Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fedra Irazoque-Palazuelos

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Reumatologia Clinica|July 29, 2011
[Epidemiology, etiology and classification]Fedra Irazoque-Palazuelos, Yaneth Barragán-Navarro
Reumatologia Clinica|July 29, 2011
[Hematomyelia in systemic lupus erythematosus and secondary antiphospholipid syndrome: case report]Fedra Irazoque-Palazuelos, Patricia V Sosa-Espinosa, Lilia Andrade-Ortega
Reumatologia Clinica|February 19, 2013
Efficacy and tolerability of rituximab in patients with rhupusLilia Andrade-Ortega, Fedra Irazoque-Palazuelos, Sandra Muñóz-López, et al.
Reumatologia Clinica|May 15, 2022
Vaccination against influenza and pneumococus in patients with rheumatoid arthritisMarco Tobar-Marcillo, Carlos Guerrero-Solís, Guillermo Osmar Pool-Valda, et al.
Reumatologia Clinica|June 8, 2012
Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0Lucio Ventura-Ríos, David Bañuelos-Ramírez, María del Carmen Hernández-Quiroz, et al.
Reumatologia Clinica|July 29, 2011
[Relapsing polychondritis: an analysis of 11 patients]Ana Cristina Pérez Gudiño, Gustavo E Lugo Zamudio, Ana S Vargas Aviles, et al.
The Lancet. Rheumatology|January 17, 2024
Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trialStanley B Cohen, Janet Pope, Boulos Haraoui, et al.
Reumatologia Clinica|July 29, 2011
[Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study]Lilia Andrade-Ortega, Fedra Irazoque-Palazuelos, Ricardo López-Villanueva, et al.
Reumatologia Clinica|July 6, 2025
Lupus nephritis in Mexican patients: Response to intensive therapyGeorgina Aguilera Barragán-Pickens, David Herrera van-Oostdam, Fedra Irazoque-Palazuelos, et al.
Lancet (London, England)|January 22, 2013
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trialJosef S Smolen, Peter Nash, Patrick Durez, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Reumatologia Clinica|July 29, 2011
[Epidemiology, etiology and classification]Fedra Irazoque-Palazuelos, Yaneth Barragán-Navarro
Reumatologia Clinica|July 29, 2011
[Hematomyelia in systemic lupus erythematosus and secondary antiphospholipid syndrome: case report]Fedra Irazoque-Palazuelos, Patricia V Sosa-Espinosa, Lilia Andrade-Ortega
Reumatologia Clinica|February 19, 2013
Efficacy and tolerability of rituximab in patients with rhupusLilia Andrade-Ortega, Fedra Irazoque-Palazuelos, Sandra Muñóz-López, et al.
Reumatologia Clinica|May 15, 2022
Vaccination against influenza and pneumococus in patients with rheumatoid arthritisMarco Tobar-Marcillo, Carlos Guerrero-Solís, Guillermo Osmar Pool-Valda, et al.
Reumatologia Clinica|June 8, 2012
Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0Lucio Ventura-Ríos, David Bañuelos-Ramírez, María del Carmen Hernández-Quiroz, et al.
Reumatologia Clinica|July 29, 2011
[Relapsing polychondritis: an analysis of 11 patients]Ana Cristina Pérez Gudiño, Gustavo E Lugo Zamudio, Ana S Vargas Aviles, et al.
The Lancet. Rheumatology|January 17, 2024
Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trialStanley B Cohen, Janet Pope, Boulos Haraoui, et al.
Reumatologia Clinica|July 29, 2011
[Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study]Lilia Andrade-Ortega, Fedra Irazoque-Palazuelos, Ricardo López-Villanueva, et al.
Reumatologia Clinica|July 6, 2025
Lupus nephritis in Mexican patients: Response to intensive therapyGeorgina Aguilera Barragán-Pickens, David Herrera van-Oostdam, Fedra Irazoque-Palazuelos, et al.
Lancet (London, England)|January 22, 2013
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trialJosef S Smolen, Peter Nash, Patrick Durez, et al.
Pageof 3